Pogach L M, Lee Y, Gould S, Giglio W, Huang H F
Department of Medicine, East Orange Veterans Administration Medical Center, New Jersey 07019.
Cancer Res. 1988 Aug 1;48(15):4354-60.
The present study examined the feasibility of using a combination of gonadotropin releasing hormone antagonist (GnRH-A) and testosterone in the prevention of procarbazine induced germinal aplasia. Daily injections of GnRH-A or vehicle were given to adult male rats for 21 days prior to procarbazine (PCB) administration and continued until 2 days after the second of two doses of procarbazine (200 mg/kg i.p.) given 1 week apart. One group of rats receiving GnRH-A and PCB was given s.c. two 5-cm testosterone capsule (TC) implants (inside diameter, 3.5 mm) immediately following the second dose of PCB. Eight weeks after the last PCB treatment, more than 99% of the seminiferous tubular cross-sections of rats receiving PCB alone were devoid of spermatogenic activity. Spermatogenesis in PCB injected animals receiving GnRH-A pretreatment alone was abortive but was partially preserved when exogenous testosterone was given following PCB administration. At 16 weeks, spermatogenesis was absent in all PCB treated animals and was only observed in less than 1% of the tubular cross-sections of the PCB treated rats receiving GnRH-A pretreatment alone. On the other hand, active spermatogenesis was noted in 68% of the tubular cross-sections, and complete spermatogenesis was noted in four of the five PCB treated rats receiving both GnRH-A pretreatment and subsequent TC implantation. At the time of sacrifice, testicular testosterone concentrations in animals receiving TC implants were below 10% of normal levels, while both serum and testicular testosterone content were increased in PCB treated animals with or without GnRH-A pretreatment. Concomitantly, testicular androgen binding protein content remained suppressed and serum androgen binding protein was elevated, indicating a prolonged defect in Sertoli cell function. These lesions were prevented by GnRH-A pretreatment. The present study demonstrates that GnRH-A pretreatment and subsequent TC implantation resulted in restoration of complete spermatogenesis in adult male rats given a 400-mg/kg cumulative dose of PCB. It is postulated that GnRH-A may ameliorate PCB induced Sertoli cell dysfunction and/or stimulate the number of spermatogonia to provide more proliferating cells ready for repopulation of the germinal epithelium following PCB injury. The differentiation of these spermatogonia was further supported by exogenous testosterone through certain unknown local mechanisms, resulting in the completion of spermatogenesis.
本研究探讨了联合使用促性腺激素释放激素拮抗剂(GnRH-A)和睾酮预防丙卡巴肼诱导的生精上皮发育不全的可行性。在给予成年雄性大鼠丙卡巴肼(PCB)之前,每天注射GnRH-A或赋形剂,持续21天,并持续至相隔1周给予的两剂丙卡巴肼(200mg/kg腹腔注射)中的第二剂之后2天。一组接受GnRH-A和PCB的大鼠在第二剂PCB后立即皮下植入两个5cm的睾酮胶囊(TC)(内径3.5mm)。在最后一次PCB治疗8周后,单独接受PCB的大鼠超过99%的生精小管横切面缺乏生精活性。单独接受GnRH-A预处理的注射PCB动物的精子发生是失败的,但在给予PCB后给予外源性睾酮时,精子发生部分得以保留。在16周时,所有接受PCB治疗的动物均无精子发生,仅在单独接受GnRH-A预处理的PCB治疗大鼠的不到1%的小管横切面中观察到精子发生。另一方面,在接受GnRH-A预处理和随后TC植入的五只接受PCB治疗的大鼠中,有68%的小管横切面观察到活跃的精子发生,四只观察到完全精子发生。在处死时,接受TC植入的动物睾丸睾酮浓度低于正常水平的10%,而无论是否接受GnRH-A预处理,接受PCB治疗的动物血清和睾丸睾酮含量均升高。同时,睾丸雄激素结合蛋白含量仍然受到抑制,血清雄激素结合蛋白升高,表明支持细胞功能存在长期缺陷。这些损伤可通过GnRH-A预处理预防。本研究表明,GnRH-A预处理和随后的TC植入可使累积剂量为400mg/kg的PCB成年雄性大鼠恢复完全精子发生。据推测,GnRH-A可能改善PCB诱导的支持细胞功能障碍和/或刺激精原细胞数量,以提供更多增殖细胞,以便在PCB损伤后重新填充生精上皮。这些精原细胞的分化通过外源性睾酮通过某些未知的局部机制得到进一步支持,从而导致精子发生的完成。